Proundly Supported by
Pfizer Foundation
    Home | Current Issue | Past Issue | Board | Instruction | Contact


Safety and Efficacy of a Simplified Fixed-Dose Combination of Stavudine, Lamivudine and Nevirapine (GPO-VIR®) for the Treatment of Advanced HIV-Infected Patients: A 24-Week Study

760

Thanomsak Anekthananon MD*,
Winai Ratanasuwan MD*, Wichai Techasathit MD*,
Areeaue Sonjai BS*, Surapol Suwanagool MD*
* Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Abstract


Objective : To determine the efficacy and safety of the fixed-dose combination of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP) in the treatment of antiretroviral naïve HIV-infected Thai adults.
Patients And Method : An open-label, single arm trial was conducted. Baseline clinical assessment and blood test was done on 101 antiretroviral naïve HIV-infected patients, who then received a fixed dose combination of d4T, 3TC and NVP (GPO-VIR®, Thai Government Pharmaceutical Organization, Bangkok, Thailand). Nevirapine was given as 200 mg once daily for the first 2 weeks. The patients were followed up at 2, 4, 8, 12 and 24 weeks. A CD4 cell count and HIV-RNA assay were done at 12 and 24 weeks.
Results : One hundred and one patients were enrolled. The mean baseline CD4 cell count and mean HIV RNA were 58.7 (57.7) cells/mm3 and 5.3 (0.5) log10 copies/mL respectively. At week 24th, the mean decrease in log HIV RNA was 3.6 (0.7) log10 copies/mL [P < 0.001; 95% confidence interval (CI), 2.70-3.03]. Eighty one (80.2%) patients had HIV RNA < 400 copies/mL by intention-to-treat analysis (ITT) and 97.6% had HIV RNA < 400 copies/mL by on-treatment analysis (OT). Sixteen (84.2%) patients with baseline HIV RNA < 100,000 copies/mL and 65 (82.3%) patients with baseline HIV RNA > 100,000 copies/mL had viral load < 400 copies/mL by ITT (P = 0.842; 95% CI, -20.9%-16.2%). Sixteen (94.1%) patients with baseline HIV RNA < 100,000 copies/mL and 65 (98.5%) patients with baseline HIV RNA > 100,000 copies/mL had viral load < 400 copies/mL by OT (P = 0.295; 95% CI, -25.5%-3.8%). The mean CD4 cell count at week 24 was 155.1 (89.0) cells/mm3 (range 13-402). The mean increase in CD4 cell count from baseline was 96.5 (63.5) cells/mm3 (P < 0.001). A total of 12% of the patients receiving d4T + 3TC + NVP developed skin rashes. Grade 3 or 4 hepatotoxicity was recognized in 7% of the patients.
Conclusion : Fixed-dose combination of d4T + 3TC + NVP (GPO-VIR®) is safe, well tolerated and effective in increasing CD4 cell counts and suppression of HIV RNA at 24 weeks in advanced HIV-infected patients in Thailand.

Keyword : Safety, Efficacy, Antiretroviral treatment, AIDS



Download Full Paper
  Vol87_No7_760.pdf  [ 106.47 Kb]

Home | Current Issue | Past Issue | Board | Instruction | Contact

© Copyright The Medical Association of Thailand. All Rights Reserved.2001-2002
Acquista Cialis generico 5 mg Effetti collaterali del Cialis 5 mg Acquista Cialis 20mg online Prezzo di Cialis originale in Svizzera Acquista Viagra in Svizzera senza prescrizione Dove comprare Cialis 10mg Viagra in farmacia online effetti collaterali Costo di Cialis 5mg Opiniones de Reduslim Acquista Spedra Avanafil senza prescrizione Acquista Viagra in Svizzera senza prescrizione Comprar Cialis original Comprar Viagra Contrareembolso Cialis 5mg Viagra sin receta Cialis 5 mg efectos secundarios graves Reduslim precio Trastorno de la ereccin venta de tadalafilo avanafil prezzo cialis 20 mg prezzo cialis effetti benefici cialis 10 mg Reduslim Kaufen pulse crypto price prediction avanafil 100 mg prezzo